Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Immunopharm Technology is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative therapeutic vaccines. The company leverages its proprietary DNA vaccine platform and advanced electroporation delivery technology to target chronic infectious diseases and oncology. Its lead candidate is a therapeutic DNA vaccine for Chronic Hepatitis B, which has progressed into Phase 2 clinical trials. Founded by experts in immunology, the company aims to provide functional cures for persistent viral infections like HBV and HIV through T-cell mediated immune responses. The firm maintains a strong focus on translational medicine and collaborative research to advance its pipeline of immunotherapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Immunopharm Technology.